Ozmosi | Atosiban Drug Profile

Product Description

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Atosiban)

Mechanisms of Action: OXTR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atosiban

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Obstetric Labor, Premature|Infertility|Pregnancy Outcomes

Phase 3: Obstetric Labor, Premature

Phase 2: Other|Obstetric Labor, Premature|Endometriosis

Trial	Phase	Trial Status	Disease	Primary Completion Date
APOSTEL 8	P4	Completed	Obstetric Labor, Premature	2024-02-29
sPTB	N/A	Completed	Obstetric Labor, Premature	2024-02-12
sPTB	N/A	Withdrawn	Obstetric Labor, Premature	2024-02-12
ChiCTR2200056942	N/A	Not yet recruiting	Unknown	2023-12-31

Date	Type	Title
04/27/2024	PubMed	The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia.
04/22/2024	PubMed	Intracerebroventricular injection of kisspeptin in male rats activates hypothalamo-pituitary-gonadal axis, but not hypothalamo-pituitary-adrenal axis.
04/22/2024	PubMed	Naloxone increases conditioned fear responses during social buffering in male rats.
09/25/2023	News Article	Lamp Carbon Black Market Global Industry Demand, Recent Trends, Share, Size, Revenue and Estimation by 2030 with Top Players
11/22/2022	News Article	XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
07/27/2021	News Article	Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
07/27/2021	News Article	Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Atosiban

Alternative Names: atosiban
Latest Update: 2024-08-05
Latest Update Note: Clinical Trial Update

Product Description

Clinical Description

Active Clinical Trial Count:

Highest Development Phases

Recent News Events

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Atosiban

Alternative Names: atosiban Latest Update: 2024-08-05 Latest Update Note: Clinical Trial Update

Product Description

Clinical Description

Active Clinical Trial Count:

Highest Development Phases

Recent News Events

Did PRYZM just deliver the data you were looking for? Did you try our Excel download too?

Alternative Names: atosiban
Latest Update: 2024-08-05
Latest Update Note: Clinical Trial Update

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?